Bioheart, Inc. Stock OTC Bulletin Board
Equities
US09062F2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2023 | U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
2023 | U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt | CI |
Financials (USD)
Sales 2021 | 201K | Sales 2022 | 82.05K | Capitalization | 3.05M |
---|---|---|---|---|---|
Net income 2021 | -3M | Net income 2022 | -2M | EV / Sales 2021 | 59.5 x |
Net Debt 2021 | 8.93M | Net Debt 2022 | 10.08M | EV / Sales 2022 | 160 x |
P/E ratio 2021 |
-0.84
x | P/E ratio 2022 |
-0.99
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.05% |
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 02-12-31 |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 17-03-04 |
Director/Board Member | 100 | 03-05-31 | |
Mark Borman
CHM | Chairman | 69 | 09-04-30 |
1st Jan change | Capi. | |
---|---|---|
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.26% | 22.19B | |
-16.16% | 21.33B | |
-7.38% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |